Package Leaflet: Information for the User
Zyllt 75 mg Film-Coated Tablets EFG
clopidogrel
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet:
Zyllt contains clopidogrel and belongs to a group of medications called antiplatelet agents. Platelets are very small cells found in the blood, and they aggregate when the blood clots. Antiplatelet agents, by preventing this aggregation, reduce the likelihood of blood clots (a process called thrombosis) forming.
Zyllt is administered to adults to prevent the formation of blood clots (thrombi) in blood vessels (arteries) that have become hardened, a process known as atherothrombosis, which can cause atherothrombotic events (such as stroke, myocardial infarction, or death).
You have been prescribed Zyllt to help prevent the formation of blood clots and reduce the risk of these serious events, as you:
have an irregular heartbeat, a disease called "atrial fibrillation", and you cannot take medications known as "oral anticoagulants" (vitamin K antagonists) that prevent the formation of new clots and prevent the growth of existing clots. You will have been told that "oral anticoagulants" are more effective than acetylsalicylic acid or the combined use of Zyllt and acetylsalicylic acid for this disease. Your doctor will have prescribed Zyllt plus acetylsalicylic acid if you cannot take "oral anticoagulants" and do not have a risk of severe bleeding.
Do not take Zyllt
If you think any of these may apply to you, or if you have any doubts, consult your doctor before taking Zyllt.
Warnings and Precautions
Before starting treatment with Zyllt, inform your doctor if you are in any of the following situations:
During treatment with Zyllt:
Children and Adolescents
This medication should not be given to children as it is not effective.
Other Medications and Zyllt
Tell your doctor or pharmacist if you are taking, have recently taken, or may take any other medication, including those obtained without a prescription.
Some medications may affect the use of Zyllt or vice versa.
You must explicitly inform your doctor if you are taking:
If you have suffered severe chest pain (unstable angina or myocardial infarction), you may have been prescribed Zyllt in combination with acetylsalicylic acid, a substance found in many medications used to relieve pain and lower fever. A dose of acetylsalicylic acid administered occasionally (not exceeding 1,000 mg in 24 hours) should not cause any problems, but prolonged use in other circumstances should be discussed with your doctor.
Taking Zyllt with Food and Drinks
Zyllt can be taken with or without food.
Pregnancy and Breastfeeding
It is preferable not to take this medication during pregnancy.
If you are pregnant or think you may be pregnant, you should inform your doctor or pharmacist before taking Zyllt. If you become pregnant while taking Zyllt, consult your doctor immediately, as it is not recommended to take clopidogrel during pregnancy.
You should not breastfeed while taking this medication.
If you are breastfeeding or plan to breastfeed, inform your doctor before taking this medication.
Consult your doctor or pharmacist before using any medication.
Driving and Using Machines
It is unlikely that Zyllt will affect your ability to drive or operate machinery.
Zyllt contains Lactose
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
Follow the instructions for administration of this medication exactly as indicated by your doctor or pharmacist. If you have any doubts, consult your doctor or pharmacist again.
The recommended dose, even for patients with a disease called "atrial fibrillation" (an irregular heartbeat), is one 75 mg Zyllt tablet per day, administered orally with or without food and at the same time each day.
If you have suffered severe chest pain (unstable angina or myocardial infarction), your doctor may prescribe 300 mg of Zyllt (4 tablets of 75 mg) to be taken once at the start of treatment. Afterward, the recommended dose is one 75 mg Zyllt tablet per day as described above.
You should take Zyllt for as long as your doctor continues to prescribe it.
If you take more Zyllt than you should
Contact your doctor or go to the emergency department of the nearest hospital, as there is a greater risk of bleeding.
If you forget to take Zyllt
If you forget to take a dose of Zyllt, but remember before 12 hours have passed since the time you should have taken the medication, take the tablet immediately and the next one at the usual time.
If you forget for more than 12 hours, simply take the next dose at the usual time. Do not take a double dose to make up for a forgotten tablet.
If you interrupt treatment with Zyllt
Do not interrupt your treatment unless your doctor tells you to. Contact your doctor or pharmacist before stopping this medication.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone will experience them.
Contact your doctor immediately if you experience:
The most common side effect reported with Zyllt is bleeding.
Bleeding can occur in the stomach or intestine, bruising, hematoma (abnormal bleeding or bruising under the skin), nosebleeds, blood in urine. A small number of cases of bleeding from the blood vessels of the eyes, intracranial bleeding, pulmonary or joint bleeding have also been reported.
If you experience prolonged bleeding while taking Zyllt
If you cut or injure yourself, the bleeding may take a little longer than usual to stop. This is related to the mechanism of action of the medication, as it prevents the blood's ability to form clots. For minor cuts or injuries, such as cutting yourself while shaving, this is usually not a problem. However, if you are concerned about your bleeding, consult your doctor immediately (see section 2 "Warnings and Precautions").
Other side effects include:
Common side effects (may affect up to 1 in 10 people):
Diarrhea, abdominal pain, indigestion, or heartburn.
Uncommon side effects (may affect up to 1 in 100 people):
Headache, stomach ulcer, vomiting, nausea, constipation, excess gas in the stomach or intestine, rash, itching, dizziness, tingling sensation, and numbness.
Rare side effects (may affect up to 1 in 1,000 people):
Dizziness, breast enlargement in men.
Very rare side effects (may affect up to 1 in 10,000 people):
Jaundice; severe abdominal pain with or without back pain; fever, difficulty breathing, sometimes associated with cough; generalized allergic reactions (such as a feeling of heat with sudden general discomfort up to fainting); swelling of the mouth; blisters on the skin; skin allergy; inflammation of the mouth mucosa (stomatitis); decreased blood pressure; confusion; hallucinations; joint pain; muscle pain; changes in taste or loss of taste of food.
Side effects with unknown frequency (cannot be estimated from available data): Hypersensitivity reactions with chest or abdominal pain, persistent symptoms of low blood sugar.
Additionally, your doctor may observe changes in the results of your blood or urine tests.
Reporting Side Effects
If you experience any side effects, consult your doctor or pharmacist, even if they are side effects not listed in this package leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date stated on the carton and blister after EXP. The expiration date is the last day of the month indicated.
Store in the original packaging to protect from light and moisture.
Medications should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medication. This will help protect the environment.
Zyllt Composition
Appearance of Zyllt and Package Contents
Film-coated tablets are pink, round, and slightly convex.
Boxes of 7, 14, 28, 30, 50, 56, 60, 84, 90, and 100 film-coated tablets in blisters.
Marketing Authorization Holder
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
Manufacturers
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
KRKA-POLSKA Sp. z o.o., ul. Równolegla 5, 02-235 Warszawa, Poland
KRKA - FARMA d.o.o., V. Holjevca 20/E, 10450 Jastrebarsko, Croatia
You can request more information about this medicinal product by contacting the local representative of the marketing authorization holder:
Belgium KRKA Belgium, SA. Tel: + 32 (0) 487 50 73 62 | Lithuania UAB KRKA Lietuva Tel: + 370 5 236 27 40 |
Bulgaria KRKA Bulgaria EOOD Tel: + 359 (02) 962 34 50 | Luxembourg KRKA Belgium, SA. Tel: +32 (0) 487 50 73 62 (BE) |
Czech Republic KRKA CR, s.r.o. Tel: + 420 (0) 221 115 150 | Hungary KRKA Magyarország Kereskedelmi Kft. Tel: + 36 (1) 355 8490 |
Denmark KRKA Sverige AB Tel: + 46 (0)8 643 67 66 (SE) | Malta
Tel: + 356 21 445 885 |
Germany TAD Pharma GmbH Tel: + 49 (0) 4721 606-0 | Netherlands KRKA Belgium, SA. Tel: + 32 (0) 487 50 73 62 (BE) |
Estonia KRKA, d.d., Novo mesto Eesti filiaal Tel: + 372 (0)6 671 658 | Norway KRKA Sverige AB Tel: + 46 (0)8 643 67 66 (SE) |
Greece QUALIA PHARMA S.A. Tel: + 30 210 6256177 | Austria KRKA Pharma GmbH, Wien Tel: + 43 (0)1 66 24 300 |
Spain KRKA Farmacéutica, S.L. Tel: + 34 911 61 03 81 | Poland KRKA-POLSKA Sp. z o.o. Tel: + 48 (0)22 573 7500 |
France KRKA France Eurl Tel: + 33 (0)1 57 40 82 25 | Portugal KRKA Farmacêutica, Sociedade Unipessoal Lda. Tel: + 351 (0)21 46 43 650 |
Croatia KRKA – FARMA d.o.o. Tel: + 385 1 6312 100 | Romania KRKA Romania S.R.L., Bucharest Tel: + 4 021 310 66 05 |
Ireland KRKA Pharma Dublin, Ltd. Tel: + 353 1 293 91 80 | Slovenia KRKA, d.d., Novo mesto Tel: + 386 (0) 1 47 51 100 |
Iceland LYFIS ehf. Tel: + 354 534 3500 | Slovakia KRKA Slovensko, s.r.o. Tel: + 421 (0) 2 571 04 501 |
Italy KRKA Farmaceutici Milano S.r.l. Tel: + 39 02 3300 8841 | Finland KRKA Finland Oy Tel: +358 20 754 5330 |
Cyprus Kipa Pharmacal Ltd. Tel: + 357 24 651 882 | Sweden KRKA Sverige AB Tel: + 46 (0)8 643 67 66 (SE) |
Latvia KRKA Latvija SIA Tel: + 371 6 733 86 10 | United Kingdom KRKA UK Ltd. Tel: + 44 (0) 207 400 3352 |
Date of the Last Revision of this Prospectus:
Detailed information about this medicinal product is available on the European Medicines Agency website http://www.ema.europa.eu/.